Journal article
High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series
Blood advances, Vol.8(20), pp.5355-5364
10/22/2024
DOI: 10.1182/bloodadvances.2024013791
PMCID: PMC11568788
PMID: 39189932
Abstract
1.Central nervous system (CNS) involvement is uncommon in HGBL, NOS, but highly prognostic for future CNS recurrence2.CNS recurrence was higher in HGBL patients with blood or marrow involvement, CD5 expression, non-GCB COO, and DEL phenotype
Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL, NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL, NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL, NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal=6, parenchymal=4, and both=1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR=3.5) and testicular (in men) or female pelvic (in women) involvement (OR=8.1). There was no significant difference in survival outcomes between HGBL, NOS patients with (median PFS=4 years) or without (median PFS=2.4 years) baseline CNS involvement (p=0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% versus 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non-GCB subtype, and DEL phenotype, however, high CNS-IPI was not. The prognosis of relapsed HGBL, NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and CAR T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease. These patients represent an unmet need and should be prioritized for experimental approaches.
Details
- Title: Subtitle
- High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series
- Creators
- Narendranath Epperla - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteAdam S. Zayac - Brown UniversityDaniel J. Landsburg - University of PennsylvaniaAllison M. Bock - Huntsman Cancer InstituteGrzegorz S. Nowakowski - Mayo ClinicEmily C. Ayers - University of VirginiaMark Girton - University of VirginiaMarie Hu - University of MinnesotaAmy Beckman - University of MinnesotaShaoying Li - The University of Texas MD Anderson Cancer CenterL. Jeffrey Medeiros - The University of Texas MD Anderson Cancer CenterJulie E Chang - University of Wisconsin School of Medicine and Public HealthHabibe Kurt - Rhode Island HospitalJose Sandoval-Sus - Moffitt Cancer CenterMohammad Ali Ansari-Lari - Moffitt Cancer CenterShalin K. Kothari - Yale UniversityAnna Kress - Yale UniversityMina L. Xu - Yale UniversityPallawi Torka - Roswell Park Comprehensive Cancer CenterSuchitra Sundaram - Roswell Park Comprehensive Cancer CenterStephen D. Smith - Fred Hutch Cancer CenterKikkeri N. NareshYasmin Karimi - University of MichiganDavid A. Bond - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteAndrew M. Evens - Rutgers Cancer InstituteSeema G. Naik - Pennsylvania State UniversityManali Kamdar - University of Colorado Cancer CenterBradley M. Haverkos - University of Colorado Cancer CenterReem KarmaliUmar Farooq - Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IAJulie M. Vose - University of Nebraska Medical CenterPaul Rubinstein - University of Illinois Urbana-ChampaignAmina Chaudhry - University of Illinois Urbana-ChampaignAdam J. Olszewski - Brown University
- Resource Type
- Journal article
- Publication Details
- Blood advances, Vol.8(20), pp.5355-5364
- DOI
- 10.1182/bloodadvances.2024013791
- PMID
- 39189932
- PMCID
- PMC11568788
- NLM abbreviation
- Blood Adv
- ISSN
- 2473-9529
- eISSN
- 2473-9537
- Publisher
- Elsevier Inc
- Grant note
A.J.O. is a clinical research scholar of the Leukemia & Lymphoma Society.
- Language
- English
- Electronic publication date
- 08/27/2024
- Date published
- 10/22/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984699045302771
Metrics
5 Record Views